Help appealing denials for this subcutaneous formulation of pembrolizumab immunotherapy.

Appeal Your Keytruda Qlex Denial

Get access to this convenient subcutaneous formulation of Keytruda.

Understanding Your Keytruda Qlex (pembrolizumab subcutaneous) Denial

Keytruda Qlex is the first subcutaneous formulation of pembrolizumab, the leading checkpoint inhibitor immunotherapy. It offers the same efficacy as IV Keytruda with a 1-2 minute injection instead of a 30-minute infusion. Insurance may initially prefer the IV formulation, but subcutaneous delivery offers important benefits for many patients.

Common Reasons for Denial

! Prior authorization required
! IV formulation required/preferred
! Must try IV Keytruda first
! Indication not approved for SC formulation
! New formulation not yet on formulary
! Cost difference concerns

How We Help

We help you document why subcutaneous administration is beneficial for you, including reduced infusion time, venous access issues, or patient preference, while demonstrating equivalent efficacy.

Start your Keytruda Qlex appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Subcutaneous pembrolizumab demonstrated equivalent pharmacokinetics and efficacy to IV pembrolizumab in clinical trials.

✓ Subcutaneous administration reduces infusion time from 30 minutes to 1-2 minutes.

✓ Patient preference and convenience are recognized as important factors in cancer treatment adherence.

✓ Subcutaneous formulations reduce burden on infusion centers and healthcare resources.

Financial Assistance Directory

Curated copay foundations, manufacturer programs, and safety-net clinics that may help with the cost while you appeal.

For your condition

CancerCare Co-Payment Assistance Foundation (opens in a new tab)

Copay assistance for chemotherapy and targeted therapies for specific cancer diagnoses. Funds open/close by cancer type.

General copay foundations & directories

NeedyMeds (opens in a new tab)

Searchable database of 5,000+ patient assistance, copay, and diagnosis-specific programs. Start here if you are not sure where to look.

Eligibility: No eligibility check - the directory itself is free. Individual programs have their own income and insurance criteria.

Patient Advocate Foundation Co-Pay Relief (opens in a new tab)

Direct copay assistance for insured patients with chronic, life-threatening, or rare conditions. Covers many disease funds.

Eligibility: Generally requires insurance coverage and income up to 400% of the federal poverty level (varies by fund).

Phone: 1-866-512-3861

HealthWell Foundation (opens in a new tab)

Independent charity providing copay, premium, and travel assistance grants across 70+ disease funds.

Eligibility: Must have insurance covering the prescribed treatment; income thresholds vary by fund. Funds open and close as donations allow.

The Assistance Fund (TAF) (opens in a new tab)

Copay, insurance premium, and travel assistance for patients with chronic and rare diseases.

Eligibility: Must have insurance and meet income limits (typically up to 500% FPL, fund-dependent).

Good Days (opens in a new tab)

Copay assistance and other support for chronic-disease patients.

Eligibility: Funds vary by disease and open/close based on availability. Usually requires insurance and income under ~500% FPL.

PAN Foundation (Patient Access Network) (opens in a new tab)

Disease-specific copay assistance funds for ~70 conditions. Funds open and close throughout the year - check the website or sign up for fund-open alerts.

Eligibility: Insurance required; income limits typically 400-500% of FPL depending on the fund.

NORD (National Organization for Rare Disorders) (opens in a new tab)

Patient assistance, copay, and travel programs for people living with rare diseases.

RxAssist Patient Assistance Program Center (opens in a new tab)

Comprehensive directory of manufacturer patient assistance programs. Search by medication to find the manufacturer's free-drug program if you are uninsured or under-insured.

Safety-net clinics & 340B

HRSA Find a Health Center (FQHC locator) (opens in a new tab)

Federally Qualified Health Centers (FQHCs) provide primary care on a sliding-fee scale and dispense many medications at 340B-discounted prices, regardless of insurance status. Often the cheapest path for uninsured or under-insured patients.

HRSA 340B Program (provider directory + program info) (opens in a new tab)

Background on the 340B Drug Pricing Program. Use to verify whether a particular clinic or hospital is a covered entity before assuming discounted pricing applies.

State Pharmaceutical Assistance Program (SPAP) directory (opens in a new tab)

State-run programs (mostly for seniors and people with disabilities) that supplement Medicare Part D and reduce prescription costs. Availability and benefits vary by state.

Medicaid eligibility & application (Healthcare.gov) (opens in a new tab)

If denied insurance is unaffordable, check Medicaid / CHIP eligibility - thresholds and pathways vary by state, and many expansion states cover adults up to 138% FPL.

Program eligibility, fund availability, and contact info change frequently. Verify with each organization before assuming a program is open.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Merck Access Program (Keytruda)

Co-pay assistance for eligible commercially insured patients. Patient assistance for uninsured/underinsured. Call 855-257-3932.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

American Cancer Society

Nationwide voluntary health organization providing cancer support, information, and advocacy.

CancerCare

Free professional support services including counseling, support groups, and financial assistance.

Cancer Support Community

Largest professionally led nonprofit network of cancer support worldwide.

Frequently Asked Questions

Yes, clinical trials demonstrated equivalent efficacy between subcutaneous and IV formulations. The active ingredient (pembrolizumab) and mechanism of action are the same.

Subcutaneous injection takes only 1-2 minutes versus 30 minutes for IV. It's also easier for patients with poor venous access, reduces time in the infusion center, and may be more convenient overall.

Keytruda Qlex is approved for adult solid tumor indications where IV Keytruda is indicated. Check with your oncologist to confirm your specific cancer type is covered.

Ready to Fight Your Keytruda Qlex (pembrolizumab subcutaneous) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Merck & Co.. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.